CN101815519B - 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法 - Google Patents

包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法 Download PDF

Info

Publication number
CN101815519B
CN101815519B CN2008801062563A CN200880106256A CN101815519B CN 101815519 B CN101815519 B CN 101815519B CN 2008801062563 A CN2008801062563 A CN 2008801062563A CN 200880106256 A CN200880106256 A CN 200880106256A CN 101815519 B CN101815519 B CN 101815519B
Authority
CN
China
Prior art keywords
treatment
escitalopram
cariprazine hydrochloride
disorder
escitalopram oxalate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801062563A
Other languages
English (en)
Chinese (zh)
Other versions
CN101815519A (zh
Inventor
N·阿德哈姆
G·萨莫里斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of CN101815519A publication Critical patent/CN101815519A/zh
Application granted granted Critical
Publication of CN101815519B publication Critical patent/CN101815519B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pregnancy & Childbirth (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801062563A 2007-08-03 2008-08-04 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法 Active CN101815519B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95369407P 2007-08-03 2007-08-03
US60/953,694 2007-08-03
PCT/US2008/072066 WO2009020897A1 (en) 2007-08-03 2008-08-04 Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands

Publications (2)

Publication Number Publication Date
CN101815519A CN101815519A (zh) 2010-08-25
CN101815519B true CN101815519B (zh) 2013-08-21

Family

ID=40338740

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801062563A Active CN101815519B (zh) 2007-08-03 2008-08-04 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法

Country Status (20)

Country Link
US (3) US20090036468A1 (cg-RX-API-DMAC7.html)
EP (1) EP2185155B1 (cg-RX-API-DMAC7.html)
JP (1) JP5460594B2 (cg-RX-API-DMAC7.html)
KR (1) KR101612563B1 (cg-RX-API-DMAC7.html)
CN (1) CN101815519B (cg-RX-API-DMAC7.html)
AU (1) AU2008283989B2 (cg-RX-API-DMAC7.html)
CA (1) CA2695519A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119828T1 (cg-RX-API-DMAC7.html)
DK (1) DK2185155T3 (cg-RX-API-DMAC7.html)
EA (1) EA018064B1 (cg-RX-API-DMAC7.html)
ES (1) ES2653852T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171908T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036004T2 (cg-RX-API-DMAC7.html)
LT (1) LT2185155T (cg-RX-API-DMAC7.html)
MY (1) MY157192A (cg-RX-API-DMAC7.html)
NO (1) NO2185155T3 (cg-RX-API-DMAC7.html)
PL (1) PL2185155T3 (cg-RX-API-DMAC7.html)
PT (1) PT2185155T (cg-RX-API-DMAC7.html)
SI (1) SI2185155T1 (cg-RX-API-DMAC7.html)
WO (1) WO2009020897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101612146B1 (ko) 2008-07-16 2016-04-12 리히터 게데온 닐트. 도파민 수용체 리간드를 함유하는 약학적 제형
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
LT2582701T (lt) * 2010-06-18 2017-03-27 Altos Therapeutics, LLC D2 antagonistai, sintezės būdai ir panaudojimo būdai
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
HUP1700253A1 (hu) * 2017-06-13 2019-01-28 Richter Gedeon Nyrt Szilárd orális gyógyszerkészítmények
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
HU231500B1 (hu) 2019-04-10 2024-04-28 Richter Gedeon Nyrt Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
KR20220009954A (ko) 2019-04-17 2022-01-25 컴퍼스 패쓰파인더 리미티드 신경인지 장애, 만성 통증을 치료하고 염증을 감소시키는 방법
JP2024537491A (ja) * 2021-10-28 2024-10-10 アッヴィ・インコーポレイテッド 大うつ病性障害の治療
AU2022409230A1 (en) * 2021-12-13 2024-06-20 Compass Pathfinder Limited Psilocybin and an adjunctive serotonin reuptake inhibitor for use in the treatment of treatment-resistant depression
EP4493274A1 (en) * 2022-03-17 2025-01-22 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
CN1829703A (zh) * 2003-08-04 2006-09-06 匈牙利吉瑞大药厂 作为d3/d2受体拮抗剂的(硫代)氨基甲酰基－环己烷衍生物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6556540B1 (en) * 1998-05-29 2003-04-29 Paradyne Corporation System and method for non-intrusive measurement of service quality in a communications network
PT1298124E (pt) * 1999-10-25 2007-05-31 Lundbeck & Co As H Método para a preparação de citalopram
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2003086393A1 (en) * 2002-04-12 2003-10-23 Sepracor, Inc. 3-aza- and 1,4-diaza-bicyclo[4.3.0]nonanes, and methods of use thereof
KR20050012284A (ko) * 2002-06-20 2005-01-31 하. 룬트벡 아크티에 셀스카브 세로토닌 재흡수 저해제가 사용되는 병용 치료법
US20070042014A1 (en) * 2003-09-04 2007-02-22 H. Lundbeck A/S Combination of a serotonin reuptake inhibitor and loxapine
HUP0500170A3 (en) * 2005-02-03 2007-11-28 Richter Gedeon Nyrt Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
HU230748B1 (hu) * 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
CN1829703A (zh) * 2003-08-04 2006-09-06 匈牙利吉瑞大药厂 作为d3/d2受体拮抗剂的(硫代)氨基甲酰基－环己烷衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NUMBERG.Managing Treatment-Emergent Sexual Dysfunction Associated with Serotogenic Antidepressants: Before and After Sildenafil.《JOURNAL OF PSYCHIATRIC PRACTICE》.2001,第7卷92-98. *

Also Published As

Publication number Publication date
CN101815519A (zh) 2010-08-25
EA201000280A1 (ru) 2010-08-30
HUE036004T2 (hu) 2018-06-28
HRP20171908T1 (hr) 2018-01-26
WO2009020897A1 (en) 2009-02-12
KR20100059830A (ko) 2010-06-04
EP2185155A1 (en) 2010-05-19
ES2653852T3 (es) 2018-02-09
AU2008283989B2 (en) 2013-12-05
KR101612563B1 (ko) 2016-04-14
EP2185155B1 (en) 2017-10-04
CA2695519A1 (en) 2009-02-12
US20120028991A1 (en) 2012-02-02
SI2185155T1 (en) 2018-02-28
NO2185155T3 (cg-RX-API-DMAC7.html) 2018-03-03
US20110015208A1 (en) 2011-01-20
JP5460594B2 (ja) 2014-04-02
HK1144784A1 (en) 2011-03-11
AU2008283989A1 (en) 2009-02-12
US20090036468A1 (en) 2009-02-05
JP2010535790A (ja) 2010-11-25
EA018064B1 (ru) 2013-05-30
DK2185155T3 (en) 2018-01-02
MY157192A (en) 2016-05-13
PL2185155T3 (pl) 2018-03-30
PT2185155T (pt) 2018-01-04
LT2185155T (lt) 2017-12-11
CY1119828T1 (el) 2018-06-27
EP2185155A4 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
CN101815519B (zh) 包含多巴胺受体配体的药物组合物和使用多巴胺受体配体的治疗方法
DeBattista et al. Antidepressant agents
US20230382885A1 (en) Enantiomeric entactogen compositions and their use
Dell’Osso et al. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects
JP2011225587A (ja) ５−ｈｔ１ａ受容体サブタイプ作動薬
US20120046302A1 (en) Methods of treating cns disorders
KR101408650B1 (ko) 무스카린성 수용체 ｍ1 길항제를 이용한 심리 질환 치료 방법
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
Perović et al. Getting the balance right: established and emerging therapies for major depressive disorders
WO2010126527A1 (en) Methods of treating cns disorders
WO2021162808A1 (en) Methods of treating pseudobulbar affect and other emotional disturbances
HK1144784B (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine recptor ligands
JP2025531623A (ja) タシピミジンおよびｃｙｐ２ｄ６阻害薬の併用療法
WO2024108195A1 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
KR20240167886A (ko) 산후 우울증의 치료를 위한 5-메톡시-n,n-다이메틸트립타민
T Chhabria et al. Recent Advances in Therapy of Schizophrenia
Seminerio Pharmacological Characterization of an Optimized Sigma Receptor Ligand
HK1116664A (en) Use of n-desmethylclozapine to treat human neuropsychiatric disease
KR20100022956A (ko) 급성 조증 치료용 카르바모일-시클로헥산

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1144784

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1144784

Country of ref document: HK